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Abstract: Levofloxacin is the synthetic L-isomer of the racemic fluoroquinolone, ofloxacin.
It interferes with critical processes in the bacterial cell such as DNA replication, transcription,
repair, and recombination by inhibiting bacterial topoisomerases. Levofloxacin has broad spectrum activity against several causative bacterial pathogens of community-acquired pneumonia
(CAP). Oral levofloxacin is rapidly absorbed and is bioequivalent to the intravenous formulation
such that patients can be conveniently transitioned between these formulations when moving
from the inpatient to the outpatient setting. Furthermore, levofloxacin demonstrates excellent
safety, and has good tissue penetration maintaining adequate concentrations at the site of
infection. The efficacy and tolerability of levofloxacin 500 mg once daily for 10 days in patients
with CAP are well established. Furthermore, a high-dose (750 mg) and short-course (5 days)
of once-daily levofloxacin has been approved for use in the US in the treatment of CAP, acute
bacterial sinusitis, acute pyelonephritis, and complicated urinary tract infections. The high-dose,
short-course levofloxacin regimen maximizes its concentration-dependent antibacterial activity,
decreases the potential for drug resistance, and has better patient compliance.
Keywords: levofloxacin, community-acquired pneumonia, pharmacodynamics, resistance,
pharmacokinetics, clinical use

Information resources
The medical literature published in any language since 1980 on levofloxacin was
searched using PuBMed, MEDLINE, and EMBASE. Additional citations were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also obtained from Ortho-McNeil Janssen
Scientific Affairs, LLC (Titusville, NJ).
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Community-acquired pneumonia (CAP) is one of the leading causes of morbidity and
mortality in adult populations.1–4 The severity and incidence of CAP are significant,
especially in the elderly and immunocompromised patients.5–7 CAP affects 6 million
people in the US annually.8 Approximately 20% (1.1–1.3 million) of these patients are
hospitalized9 with estimated cost of about US$25,000 per hospitalization10 resulting in
over US$30 billion annual costs for hospitalizations alone; 12% of patients hospitalized
for CAP die.9 In patients with severe CAP requiring admission to the intensive care
unit (ICU), mortality increases to up to 30%.11–14 The most common cause of CAP is
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Streptococcus pneumonia.15–18 Other bacterial causes include
Haemophilus influenzae, Moraxella catarrhalis, Klebsiella
pneumoniae, and the “atypical” CAP pathogens which include
Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila.2,17,19–22 Severe CAP, generally requiring
admission to the ICU for management, is frequently caused by
Staphylococcus aureus and Gram-negative bacilli.13,23–25
Epidemiologic studies reveal that pathogenic organisms
are not recovered in .50% of patients exhibiting clinical
signs and symptoms of CAP. Thus, microbiological information is frequently unavailable to refine initial empiric antibiotic treatment of CAP in either hospitalized and outpatient
settings.9,23,25 The guidelines from the Infectious Diseases
Society of America/American Thoracic Society recommend
initial empiric therapy with a respiratory fluoroquinolone
(eg, levofloxacin 750 mg, moxifloxacin, or gemifloxicin) or
a β-lactam plus a macrolide. In adults, fluoroquinolones are
recommended for the treatment of CAP caused by penicillinsusceptible S. pneumoniae, penicillin-resistant S. pneumoniae,
Legionella pneumophilia, H. influenzae, M. pneumoniae, and
C. pneumoniae. Levofloxacin combination therapy with an
antipseudomonal β-lactam (or aminoglycoside) should be
considered if Pseudomonas aeruginosa infection is a likely
cause of pneumonia.24 Antibiotic resistance in S. pneumoniae
has been a major problem in the US and worldwide for more
than a decade.26 Furthermore, increasing rates of antibiotic
resistance (most notably, penicillin, cephalosporin, and
macrolide resistance) observed in bacteria that commonly
cause CAP have resulted in increased treatment failures and
inferior clinical outcomes for many patients with CAP.14,15,27–30
Although there are reports of the emergence of resistance
to some fluoroquinolones among S. pneumonia,26 the incidence of levofloxacin-resistant organisms has remained
steady with resistance rates of ,1% worldwide.31–35
Levofloxacin (Figure 1) is a light yellowish-white
crystal or crystalline powder with a molecular weight of
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Figure 1 Structure of levofloxacin.
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370.38 g/mol. It interferes with critical processes in the
bacterial cell, such as DNA replication, transcription, repair,
and recombination, by inhibiting bacterial topoisomerases.
Human cells lack these topoisomerases, which are essential
for bacterial DNA replication, providing specificity against
bacterial DNA topoisomerases that are responsible for
separating the strands of duplex bacterial DNA, inserting
another strand of DNA through the break, and then resealing
the originally separated strands.36,37 Levofloxacin is active
against a broad range of Gram-positive, Gram-negative, and
cell-wall-deficient (atypical) bacteria that may be causative
pathogens in community-acquired and nosocomial infections.
Levofloxacin is a well-established treatment option for
respiratory and urinary tract infections (UTI), particularly
since levofloxacin is active against some penicillin – and
macrolide-resistant species (eg, S. pneumoniae – the most
common causative pathogen for community-acquired bacterial respiratory infections).31–34,38,39 The incidence of penicillin- and macrolide-resistance in many bacterial species is both
high and widespread.40 In the US, a high-dose, short-course
regimen of levofloxacin (750 mg once daily for 5 days) is
approved for the treatment of adults with CAP, acute bacterial
sinusitis (ABS), complicated UTI, and acute pyelonephritis
(AP). The use of levofloxacin, including some data on the
high-dose, short-course treatment regimen, has been reviewed
previously.39 This review focuses on the pharmacology of
levofloxacin in the treatment of CAP.

Pharmacodynamic properties
Spectrum of activity
Levofloxacin is the L-isomer of the racemic fluoroquinolone ofloxacin.39,41 Topoisomerase IV is the main target
for levofloxacin in Gram-positive bacteria and DNA gyrase
(topoisomerase II) is the target in Gram-negative bacteria.42
Levofloxacin has a broad spectrum of antibacterial activity that includes several Gram-positive and Gram-negative
aerobes and cell-wall-deficient (atypical) bacteria. The
minimum inhibitory concentrations (MIC) of levofloxacin
required to inhibit the growth of 90% of clinical isolates
(MIC90) are used as assessments of the in vitro activity of
levofloxacin. The levofloxacin MIC breakpoints for S. pneumoniae defined by the Clinical and Laboratory Standards
Institute are: #2 mg/L (susceptible), 4 mg/L, (intermediate), and $8 mg/L (resistant).41,43 Also, levofloxacin
generally demonstrates good in vitro activity against penicillin-resistant S. pneumoniae strains. S. pneumoniae with
reduced susceptibility to penicillin commonly cause CAP. The
levofloxacin MIC90 for penicillin-susceptible, -intermediate,
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and -resistant isolates of S. pneumoniae was 1 mg/L in
multiple studies, with .97% of isolates testing susceptible
to the drug.31–34,38,44
Levofloxacin has variable activity against S. aureus,
depending on methicillin susceptibility. Levofloxacin
had MIC90 values of 0.25–4.0 mg/L against methicillinsusceptible S. aureus isolates, whereas methicillin-resistant
S. aureus isolates exhibited levofloxacin resistance, MIC90
values ranging from .4 to $64 mg/L.38,44–46 The in vitro
activity of levofloxacin against Enterococcus faecalis was
limited (MIC90 of 8 to $32 mg/L in vancomycin-susceptible
and -resistant strains). Although levofloxacin has limited
activity against coagulase-negative staphylococci (.4 mg/L,
54.1%).45 It has demonstrated good in vitro activity against a
range of other Gram-positive bacteria, such as Streptococcus
pyogenes (1 mg/L, 99.9%)32,33 and other β-hemolytic streptococci (0.5–1 mg/L, 99.1%–100%).47
Generally, levofloxacin has good in vitro activity against
Gram-negative bacteria including the common respiratory
tract pathogens H. influenzae.31,35,38,44,48–50 Haemophilus
parainfluenzae,50 and M. catarrhalis31,35,44,48–50 as well as
urinary tract pathogens (K. pneumoniae,38,44,51 Enterobacter
cloacae,38,44,51–53 and Proteus mirabilis38,45,48). The values of
MIC90 for levofloxacin against isolates of H. influenzae,
H. parainfluenzae, and M. catarrhalis were #0.06 mg/L
with nearly 100% susceptibility rates. Levofloxacin was
also highly active against β-lactamase-positive isolates of
H. influenzae31–34,38 and M. catarrhalis,31,44,48–50,54,55 However,
the activity of levofloxacin is variable against Escherichia
coli and P. aeruginosa. The MIC90 of levofloxacin against
E. coli ranged from #0.06 mg/L (susceptible) to .8 mg/L
(resistant).38,44,45,51,56 Levofloxacin showed lower levels of
activity against isolates of P. aeruginosa, MIC90 values
ranging from 0.5 mg/L to 64 mg/L and susceptibility rates
of 71%–94%.38,44,45,48,51 Levofloxacin also had limited activity against extended-spectrum β-lactamase-producing
K. pneumoniae (MIC90 of .8–32 mg/L).45 Levofloxacin
has good activity against the cell-wall-deficient (atypical)
organisms C. pneumonia.57–60 L. pneumophila,38,44,48,57,61,62, and
M. pneumonia,48,57,63–65 MIC90 values being #2 mg/L.

Bactericidal activity
The bactericidal activity of levofloxacin is concentrationdependent,66 and the minimum bactericidal concentration
(MBC) of levofloxacin was #4× the MIC against the majority
of isolates for a number of causative pathogens of respiratory tract infections.59,60,64,65,67 The MBC90 of levofloxacin
was 1–4× the MIC against the majority of M. pneumoniae
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isolates (MBC of #0.5–1.0 mg/L), as reported by multiple
authors.59,60,63–65,67 The MBC of levofloxacin was 1–2× the
MIC (#0.06–4 mg/L) against K. pneumoniae, P. aeruginosa,
E. coli, and E. cloacae.51 Levofloxacin has a post-antibiotic
effect (PAE) of 2.0–4.5 hours depending on the pathogen.39
The PAE of levofloxacin against S. pneumoniae was up
to 4.5 hours at 10× the MIC. Furthermore, levofloxacin
has shown PAEs against methicillin-susceptible S. aureus
(MSSA), K. pneumoniae, L. pneumophila, and anaerobes39
as well as against erythromycin-resistant and -susceptible
strains of L. pneumophila.61

Resistance
Resistance to antibacterial drugs in S. pneumoniae has been
a major problem in the US for more than a decade.26 The
primary cause of reduced susceptibility of bacteria (particularly S. pneumoniae) to fluoroquinolones is at least one
mutation in the parC and parE genes that code for DNA
topoisomerase IV or gyrA and gyrB genes that code for DNA
gyrase.68,69 Another fluoroquinolone resistance mechanism
involves active drug efflux through mutation in the efflux
regulatory genes mexR and nfxB.68,70 Although there are
reports of the emergence of fluoroquinolone resistance among
S. pneumoniae,26 the incidence of levofloxacin-resistant organisms has remained stable to date at #1% worldwide.31–35
In the worldwide PROTEKT surveillance program
between 1999 and 2000, levofloxacin-resistant isolates of
S. pneumoniae were identified; 94% of these isolates had
at least one mutation in the genes coding for topoisomerase
IV as well as in the genes coding for DNA gyrase.69 The
SENTRY surveillance program (1997–2005) identified
fluoroquinolone-resistant isolates of β-hemolytic Streptococcus spp. as having significant mutations in the parC or gyrA
gene, or both. Only mutations in parC were associated with
lower MIC values.47 A report of an in vitro pharmacodynamic
model simulating the concentration of levofloxacin in the
epithelial lining fluid (ELF) after once daily administration
of 500 mg revealed that all five isolates of S. pneumoniae
containing the first-step parC mutation had levofloxacin
resistance within 48 hours ($16-fold increase in MIC) and
four of the isolates acquired a second-step (gyrA) mutation.71
The acquisition of a second-step mutation appeared to be
related with an area under the concentration–time curve
(AUC):MIC ratio of #256; this indicates that to prevent
levofloxacin resistance from being acquired in isolates
with a first-step parC mutation, the AUC:MIC ratio target
should be .256.71 When the range of free AUCs (fAUCs) of
levofloxacin and other fluoroquinolones were simulated, the
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results demonstrated that fAUC:MIC ratios of #82 and #86
for levofloxacin were associated with a first-step parC mutation and second-step gyrA mutation in S. pneumoniae. These
resistance breakpoints for levofloxacin were significantly
higher (P # 0.001) than those for other tested fluoroquinolones (gatifloxacin, gemifloxacin, and moxifloxacin) using post
hoc analysis. Furthermore, the higher the fAUC:MIC ratio
for each fluoroquinolone, the more delay in the development
of first- or second-step mutations was observed.72
In the SENTRY (worldwide, 1997–2004),47 PROTEKT
(US and Canada, 1999–2002), 32–34 and TRUST (US,
1998–2002)35 surveillance programs, the overall levofloxacin resistance rate in S. pneumoniae isolates was #1%; in
penicillin-resistant isolates, the overall rate of levofloxacin
resistance was 0.9%–2.7%.31,34,35 In the TRUST surveillance
program from 2001 to 2005, the rate of S. pneumoniae
resistance to levofloxacin changed from 0% to 0.5% and the
resistance of these isolates to penicillin resistance increased
from 27.4% to 28.9%. Amoxicillin/clavulanic acid resistance
increased from 6.5% to 12.9%, and clindamycin resistance
increased from 12.1% to 18.6%.73 The levofloxacin 750 mg
dose has been directly compared to imipenem–cilastatin
in the treatment of nosocomial pneumonia. The average
age of the patients was 55 years and 438 patients were
randomized. Forty-two percent of patients in the levofloxacin
arm were $65 years of age. The clinical success rate in the
intention-to-treat population was 66.2% in the levofloxacin
arm vs 69.4% in the imipenem arm. In the clinically evaluable population, the success rates were 59.3% and 62.5%
for levofloxacin and imipenem, respectively.74 Other data
from 1998 and 2005 revealed that the levofloxacin-resistant
isolates of H. influenzae or M. catarrhalis could not be
identified in large worldwide surveillance studies.32–34,49,54,55
However, surveillance studies have demonstrated resistance
to levofloxacin in MSSA and methicillin-resistant strains of
S. aureus (MRSA) (3.4%–10.1% and 76.6%–79.2%, respectively) and P. aeruginosa (24.7%).45,46,56

Pharmacokinetics and metabolism
Levofloxacin is rapidly absorbed after oral administration
and shows linear pharmacokinetics for both single- and
multiple-dose (once daily) regimens. The oral solution and
tablet formulations are bioequivalent to the intravenous formulation.41 The mean pharmacokinetic parameters obtained
in different studies of intravenous and oral levofloxacin in
healthy adults75,76 are comparable to those reported in the
manufacturer’s US prescribing information.41 The peak
plasma concentration (Cmax) after single 750 mg doses of
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levofloxacin given to healthy volunteers was 11.3 mg/L75
and 12.1 mg/L for intravenous administration, compared
with 7.1 mg/L76 and 9.3 mg/L41 for oral administration. When
given in multiple doses levofloxacin had Cmax of 12.1 mg/L
and 12.4 mg/L for intravenous administration compared with
8.6 mg/L for oral ones.41,76 Levofloxacin steady-state conditions were reached within 48 hours of initiating once-daily
intravenous or oral 750 mg.41 After oral administration, the
Tmax of levofloxacin is reached within 1–2 hours with an
absolute bioavailability of oral levofloxacin 500 mg and
750 mg of approximately 99%.41,75,76 Systemic exposure to
levofloxacin was similar for the intravenous and oral formulations upon administering equal doses of levofloxacin.41
The AUC24 was 103 mg h/L75 and 90.7 mg h/L76 at steady
state after intravenous or oral administration of levofloxacin
750 mg once daily, respectively.
The in vitro studies revealed that 24%–38% of levofloxacin was bound to plasma proteins (mainly albumin) and the binding was independent of levofloxacin
concentration.41 The volumes of distribution obtained in
pharmacokinetic studies ranged from 74–112 L after single
or multiple doses of levofloxacin 500 mg or 750 mg.75,76
Levofloxacin is distributed extensively in tissues and fluids
throughout the body and accumulates in phagocytic cells.39
Furthermore, the mean concentrations of levofloxacin in
tissues, ELF, alveolar macrophages, polymorphonuclear
leukocytes, paranasal sinus mucosa, and urine, surpass the
concentration of levofloxacin in the plasma.39,77–83 It has
been reported that the paranasal sinuses mucosa:plasma
concentration ratio was 2.56 at Tmax after a single 500 mg
oral dose of levofloxacin. The concentration of levofloxacin
in the paranasal sinuses mucosa was generally higher than
the MIC90 of the common causative pathogens for upper
respiratory tract infections (0.008–2.0 mg/L), including
penicillin-susceptible, -intermediate, and -resistant isolates
of S. pneumoniae.82 In healthy volunteers, oral levofloxacin
(500 or 750 mg) had a mean ELF:plasma concentration
ratio at steady state of 1.16 using population pharmacokinetic modeling and 3.18 using Monte Carlo simulation.82
At a lower dosage of levofloxacin (500 mg once daily for
3 days), Cmax and AUC24 values for the drug were significantly (P , 0.01) higher in the polymorphonuclear leukocytes than in plasma.84 Reassuringly, the concentrations of
levofloxacin in the ELF and alveolar macrophages were
1.5- to 6-fold higher than that in the plasma at steady state
after receiving levofloxacin 500 mg once daily for 5 days
in older patients undergoing diagnostic bronchoscopy with
a mean age of 62 years.80
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Levofloxacin is eliminated mainly through the kidneys,
75%–87% of the dose excreted being unchanged in the
urine within 48–72 hours of administering oral levofloxacin
500 or 750 mg; ,4% is excreted in the feces.41,75,76 After a
single dose of levofloxacin 750 mg, the mean drug concentration in the urine was 475 mg/L at 4 hours and 186 mg/L
at 24 hours;77 ,5% of the dose is excreted in the urine as
inactive metabolites of levofloxacin.41 The mean total body
clearance (CL) of levofloxacin in healthy volunteers was
reported as 8–9.4 L/h75,76 and 8.6–13.6 L/h.41 Levofloxacin
appears to undergo glomerular filtration as well as tubular
secretion.41 After single or multiple doses of oral or intravenous levofloxacin 750 mg, the mean terminal plasma elimination half-life (t1/2β) is 7.5–8.8 hours in pharmacokinetic
studies.75,76 The t1/2β of levofloxacin is increased and the CL
reduced in patients with impaired renal function (creatinine
clearance CLCR , 50 mL/min); therefore dosage adjustment
is required to avoid drug accumulation as shown in Table 1.41
Furthermore, levofloxacin is not cleared effectively by hemodialysis or continuous ambulatory peritoneal dialysis.39,41
The pharmacokinetic properties of levofloxacin are not
influenced by age, gender, or race, and they do not show
noticeable differences between healthy adults, patients with
HIV,39 or patients with severe community-acquired bacterial
infections.41 Levofloxacin pharmacokinetics in hepaticallyimpaired patients have not been investigated; however,
because of the limited hepatic metabolism of levofloxacin,
hepatic impairment is unlikely to have a prominent effect on
the drug pharmacokinetics.41

Clinical efficacy
The efficacy of levofloxacin 750 mg once daily (intravenous and oral) for 5 days in adults with CAP,66 ABS,85 and
complicated UTI86,87 has been assessed in several randomized, double-blind, multicenter, noninferiority trials.66,85–87
Table 1 Dosing in patients with diminished renal function
Renal status

Initial dose

Subsequent dose

CLCR $ 50 mL/min
CLCR 20–49 mL/min
CLCR 10–19 mL/min
Hemodialysis
CAPD
CLCR $ 50 mL/min
CLCR 20–49 mL/min
CLCR 10–19 mL/min
Hemodialysis
CAPD

500 mg
500 mg
500 mg
500 mg
500 mg
750 mg
750 mg
750 mg
750 mg
750 mg

500 mg q24h
250 mg q24h
250 mg q48h
250 mg q48h
250 mg q48h
750 mg q24h
750 mg q48h
500 mg q48h
500 mg q48h
500 mg q48h

Abbreviations: CLCR, creatinine clearance; CAPD, chronic ambulatory peritoneal
dialysis; q, every.
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The endpoints were the clinical success rate (proportion of
patients showing either a clinical cure or improvement with
no need for further antimicrobial therapies in both situations)
1–2 weeks after the end of treatment,66 or at 2–3 weeks of the
study,85 or the microbiological eradication rate (all pathogens
identified in samples at the study entry were eradicated) at
2–3 weeks of the study.86,87 Levofloxacin indications and
dosing for patients with normal renal function are summarized in Table 2.
Patients enrolled in the noninferiority trial with CAP
were aged $18 years and were diagnosed with mild-tosevere CAP. Other inclusion criteria involved one or more
signs or symptoms including fever, a white blood cell count
of .10,000 cells/mm3, or hypothermia. The exclusion criteria included the following conditions: patients without
a confirmed diagnosis of CAP, patients who did not come
to the follow-up visit, patients who increased (.120%) or
reduced (,80%) the scheduled doses, and patients who
had additional antimicrobial therapy during treatment with
levofloxacin.66 Patients with mild-to-severe CAP received
750 mg levofloxacin (intravenous or oral) once daily for
5 days or 500 mg once daily for 10 days. Subjects receiving the higher dosage of levofloxacin were given a placebo
for the last 5 days of the 10-day treatment regimen. 66
Levofloxacin susceptibility testing of the causative pathogens was performed, but initial treatment was empirical. The
noninferiority criteria were established as the upper limit
of the 2-sided 95% CI for the between-group difference in
the clinical success rate ,15%, if both treatment groups
had a clinical success rate of 80%–90%, or ,10%, if both
treatment groups had a clinical success rate of $90%.66
The results revealed that levofloxacin 750 mg once daily for
5 days was noninferior to 500 mg once daily for 10 days in
the treatment of mild-to-severe CAP in the overall patient
population,66 as well as for patients with CAP caused by
atypical organisms (C. pneumoniae or M. pneumoniae),88
and for elderly patients aged $65 years.89
Table 2 Levofloxacin indications and dosing for patients with
upper respiratory tract infections and with normal renal function
Type of infection

Dose

Frequency

Duration

Community acquired pneumonia
Community acquired pneumonia
Nosocomial pneumonia
Acute bacterial exacerbation
of chronic bronchitis
Acute bacterial sinusitis
Acute bacterial sinusitis

500 mg
750 mg
750 mg
500 mg

q24h
q24h
q24h
q24h

7–14 days
5 days
7–14 days
7–14 days

500 mg
750 mg

q24h
q24h

10–14 days
5 days

Abbreviation: q, every.
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In patients receiving either the levofloxacin 750 mg or
500 mg regimen, baseline characteristics were similar and
overall microbiological eradication rates were similar in
both groups.66 The eradication rates for both the 750 mg
and 500 mg regimens were high for subgroups of microbiologically evaluable patients infected with aerobic Grampositive (82.8% vs 85.3%) and Gram-negative (96.2% vs
90.7%) pathogens, as well as other pathogens (93.8% vs
96.2%). Eradication rates for S. pneumoniae, H. influenzae,
and H. parainfluenzae in the corresponding post-therapy
visit were 86.4% vs 85%, 92.3% vs 85.7% and 100% vs
90%, respectively.66 Retrospective analysis revealed that
the clinical success rates in patients with CAP caused by
H. influenzae, H. parainfluenzae, or S. pneumoniae were
also similar between the levofloxacin 750 mg and 500 mg
treatment groups (92.3% vs 92.9%, 100% vs 90%, and 90.9%
vs 90%, respectively).66
The efficacy of the high-dose, short-course of levofloxacin in achieving early resolution of symptoms has been
studied.90 Resolution of purulent sputum, shortness of breath,
chills and cough were 40.6% vs 30.7%, 35.1% vs 27.7%,
54.8% vs 54.2%, and 10% vs 10.1% comparing patients who
received the levofloxacin 750 mg or 500 mg regimen, respectively. Furthermore, 99.4% of the 158 pathogens isolated at
study entry were susceptible to levofloxacin and there was
no significant difference between treatment groups in the
time of switching from the intravenous administration of
levofloxacin to oral administration of the drug.90 High-dose,
short-course of levofloxacin (750 mg once daily for 5 days)
also had good efficacy in the subgroup of patients with severe
CAP, demonstrating high clinical success rates of .85%.
Overall, high microbiological response rates ($87.5%) were
observed in the subgroup of microbiologically evaluable
patients receiving levofloxacin regardless of the treatment
regimen.91 In the same study, microbiological eradication
was observed in 88.2% of typical pathogens identified from
respiratory cultures and 90% of atypical pathogens.91
It has been reported that levofloxacin 750 mg once daily
for 5 days has good efficacy in patients with CAP caused
by atypical organisms.88 The overall clinical success rate
of levofloxacin 1–2 weeks after treating CAP caused by
a single atypical pathogen, was .95%. Noninferiority of
levofloxacin 750 mg once daily for 5 days compared with the
10-day regimen was also established in this study. The overall
clinical success rate of the levofloxacin 750 mg regimen was
94.8% for CAP caused by atypical pathogens, compared with
96.5% for the levofloxacin 500 mg regimen.88 Furthermore,
the clinical success rates at the 1–2 weeks post-treatment
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visit for patients with C. pneumoniae, L. pneumophila,
and M. pneumoniae were comparable between the groups
receiving the levofloxacin 750 mg and 500 mg dosing regimen (90.9% vs 100%, 100% vs 100%, and 95.3% vs 94.4%,
respectively).88

Post-marketing surveillance
Post-marketing data demonstrated that levofloxacin simultaneous administered with warfarin may increase the prothrombin time. Therefore, coagulation studies and bleeding
should be monitored in patients receiving the two drugs
concomitantly.41 Levofloxacin does not currently have a
US Food and Drug Administration approved indication
in patients aged ,18 years. Like other fluoroquinolones,
levofloxacin decreases theophylline metabolism and dosage
adjustment for theophylline may be required for concurrent
administration of both drugs. Concomitant fluoroquinolone
administration with cyclosporin resulted in elevated serum
concentrations of ciclosporin, but these alterations were
not clinically significant.41

Safety and tolerability
Intravenous levofloxacin must be administered slowly as an
infusion over a minimum period of 60–90 minutes, depending
on the dose. Levofloxacin tablets or oral solution are generally prescribed at dosages of 250, 500, or 750 mg once daily.
The tablet formulation of levofloxacin can be taken with or
without food; however, the oral solution should be taken
1 hour prior to or 2 hours after meals. In patients receiving
levofloxacin, sufficient hydration should be maintained to
prevent excessively concentrated urine. Levofloxacin should
be administered at least 2 hours apart from some agents such
as magnesium- or aluminium-containing antacids, sucralfate,
metal cations, zinc-containing multivitamins, or didanosine.
Data from patients aged $65 years (phase III clinical
trials) demonstrated no difference between elderly and younger
patients for safety or effectiveness of levofloxacin. Elderly
patients may be more sensitive to levofloxacin, mainly due to the
effect of the drug on the QT interval. Thus, caution is required in
the simultaneous administration of levofloxacin with drugs that
prolong the QT interval such as class IA or class III antiarrhythmics. Although, levofloxacin is a very safe fluoroquinolone,
caution and a risk/benefit assessment is required with the use
of levofloxacin in the elderly due to the increased risk of severe
tendon disorders in this group of patients, particularly if they
are receiving corticosteroids.41 However, it should be stated that
there is no evidence that tendon rupture is more likely to occur
with levofloxacin than with any other fluoroquinolone.92 Blood
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glucose monitoring is recommended in patients with diabetes
mellitus receiving simultaneous hypoglycemic agents and/or
insulin, because symptomatic hyperglycemia and hypoglycemia have been reported with levofloxacin administration.41
Concomitant administration of fluoroquinolones (including
levofloxacin) with NSAIDs may increase the risk of central
nervous system stimulation and convulsive seizures.41
Levofloxacin 750 mg once daily for 5 days is a welltolerated fluoroquinolone for patients with CAP or UTI.86,87,93
In a pooled analysis of patients with respiratory infections
receiving the levofloxacin 750 mg regimen or 500 mg regimen, the results revealed that 4.5% and 4.9% of patients,
respectively, had adverse effects during the therapy. The
adverse effects in both dosage regimens included nausea,
vomiting, diarrhea, dyspepsia, constipation, abdominal
pain, headache, insomnia, and dizziness. The incidence of
levofloxacin-associated adverse effects was similar between
both treatment regimens (8% vs 7.6%).93
The use of fluoroquinolones and exposure to the sun or
UV light has been associated with photosensitivity reactions.41
Fluoroquinolones can potentially prolong the QT interval
but there are no reported cases of torsade de pointes in any
clinical or post-marketing trials.41,93 It has been reported
that levofloxacin is associated with Clostridium difficile
diarrhea, as are most other antibacterial agents. Severity
ranges from mild diarrhea to pseudomembranous colitis.41
The incidence of drug-related adverse effects in patients with
CAP or ABS was similar between the levofloxacin 750 mg
and 500 mg dosing regimens.93

Regulatory affairs
Levofloxacin is approved for use in the US, Canada, and
worldwide in the treatment of CAP, ABS, complicated UTI,
and AP.

Conclusion and comments
The respiratory fluoroquinolones are considered to be a substantial component of the anti-infective armamentarium for the
treatment of bacterial respiratory infections. Levofloxacin is
active against most of the respiratory pathogens and has a good
clinical success rate. Its favorable pharmacodynamics, safety,
efficacy profile, and tolerability, and also its in vitro activity
against the common respiratory pathogens, places levofloxacin among first-line agents for the treatment of communityacquired respiratory tract infections such as CAP.
The Infectious Diseases Society of America/American
Thoracic Society guidelines recommend that a respiratory
fluoroquinolone (eg, levofloxacin 750 mg) or a β-lactam
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plus a macrolide be used for the treatment of CAP. The use
of fluoroquinolones is a reasonable therapeutic choice for
the treatment of respiratory infections caused by penicillinsusceptible S. pneumoniae, penicillin-resistant S. pneumoniae,
Legionella pneumophilia, H. influenzae, M. pneumoniae,
and C. pneumoniae. Levofloxacin combination therapy with
antipseudomonal β-lactam (or aminoglycoside) should be
considered if P. aeruginosa is likely to be a causative pathogen of the respiratory infection. S. pneumoniae resistance
to antibacterial drugs has been a major problem in the US
and worldwide for more than a decade. Although there are
reports of the emergence of resistance to some fluoroquinolones among S. pneumoniae, the incidence of levofloxacinresistant organisms has remained steady at ,1% worldwide.
In general, levofloxacin shows good in vitro activity against
clinically relevant Gram-positive, Gram-negative, and atypical organisms that cause respiratory infections. Levofloxacin
is active against penicillin-susceptible and -resistant strains
of S. pneumoniae, the Gram-negative species E. cloacae
and P. mirabilis, and the atypical organisms C. pneumoniae,
L. pneumophila, and M. pneumoniae (MIC90 of #2 mg/L).
Levofloxacin is highly active against the Gram-negative species
H. influenzae, H. parainfluenzae, and M. catarrhalis (MIC90
of #0.06 mg/L), including β-lactamase-positive strains of H.
influenzae and M. catarrhalis. Because the activity of levofloxacin is concentration-dependent, the most common predictor of microbiological and clinical efficacy is the AUC:MIC
ratio. A ratio of .30 was used in some studies to predict in
vivo activity, particularly against S. pneumoniae. A higher ratio
(.100) is suggested as being predictive of a bactericidal effect,
and thus reducing the potential of first-step mutations. Availability of pneumococcal vaccine is decreasing the incidence
of pneumococcal infections and decreasing the incidence of
infections caused by resistant S. pneumoniae.
In the last 5 years, the rate of resistance of S. pneumoniae
to amoxicillin/clavulanic acid, azithromycin, and tetracycline
appears to have increased, but the levofloxacin resistance rate
of S. pneumoniae remains #1% worldwide.94 High-dose,
short-term therapy (levofloxacin 750 mg once daily for 5 days)
is the standard dosing regimen for levofloxacin in the treatment of CAP worldwide. Increased availability of pneumococcal vaccination programs may decrease the incidence of
S. pneumoniae as a cause of CAP in adults over time. Other
problematic infections with multidrug-resistant organisms will
become the main focus of research in the next 5 years.
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